Sam Chun Dang Pharm corrects disclosure to add new macular degeneration drug item to Canada, Middle East supply deals

• SCD corrected its prior disclosure on an Apotex deal covering exclusive Canadian supply and sales rights for its SCD411 aflibercept biosimilar.
• The correction adds a new macular degeneration product for Canada plus six Middle East countries under an additional agreement dated Oct. 1, 2026.
• Contract terms for the added product remain undisclosed due to the partner’s confidentiality request, with an embargo set through Oct. 1, 2036.
• The filing adds a risk item: termination of the added-product agreement could trigger a termination fee within previously received milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCD - Sam Chun Dang Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001900395), on October 01, 2026, and is solely responsible for the information contained therein.